Article ID Journal Published Year Pages File Type
6192414 Journal of Thoracic Oncology 2016 31 Pages PDF
Abstract
In an adjusted comparison across separate clinical trials, ceritinib was associated with prolonged OS and PFS compared with crizotinib when used as initial ALK-targeted therapy for previously treated ALK-positive NSCLC.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls
Authors
, , , , , , , , , , ,